

Blue Bees Therapeutics announces the appointment of Dr Marie-Noëlle Ly as its chief development officer and Thomas-Paul Descamps as board member.

Orsay, France, May 27th, 2024, Blue Bees Therapeutics, a biopharmaceutical company specialized in the development of first-in-class immunotherapy to treat cancer, announces today:

- The appointment of Dr Marie-Noëlle Ly as Chief Development Officer (CDO) in charge of the regulatory preclinical development of the Company's products up to the first-in-human trials. Marie-Noëlle also joins the Company's executive committee.
- The appointment of Mr Thomas-Paul Descamps as independent non-executive director to join the company's board of directors.

Philippe Berthon, Chairman of the board and CEO of Blue Bees Therapeutics, commented: *"I am delighted to welcome Marie-Noëlle as our Chief Development Officer. With her extensive track record in the biotech industries, she is best suited to lead the preclinical development and strategy of our lead candidate, BB10x, to enter phase 1/2 clinical trial."* Philippe added: *"I am also very pleased that Thomas-Paul is joining the Blue Bees Therapeutics board as an independent non-executive director. Thomas-Paul is a highly experienced biotech and pharma manager. I expect him to add significant value to the Company through his corporate and business development skills"*.

Dr Marie-Noëlle Ly: Marie-Noëlle has held positions as head of pharmaceutical development, from the preclinical stage up to the CTA/IND for the launch of Phase I to Phase III clinical trials, at Quantum Genomics, at Biophytis. Prior to these positions, she managed the drug formulation activity at Drugabilis for six years. Marie-Noëlle obtained her PharmD from Université Paris-Saclay and holds a master's degree in drug production.

Thomas-Paul Descamps: Thomas-Paul is currently CEO of Jellagen based in UK, and has held senior positions in sales, marketing and business development at Actelion, Ipsen and Allergan, previously in global pharmaceutical players. Furthermore, he held for the last 15 years, board sits in several biotech companies and has successfully raised £15M+. Thomas-Paul holds a master's degree in general management from the University Paris IX Dauphine and a diploma of finance and marketing from Sciences-Po Paris.

About Blue Bees Therapeutics: Blue Bees Therapeutics is a biotechnology company founded in 2022, dedicated to the development of first-in-class immunotherapies for the treatment of cancer, based on a breakthrough technology discovered by the team led by Dr Michel Léonetti, within the Department of Medicines and Healthcare Technologies from CEA Paris-Saclay. Blue Bees Therapeutics technology consists of protein complexes combining an antibody activating a receptor selectively expressed on the surface of immune cells, with a ligand of Heparan Sulfate Proteoglycans (HSPGs). Potentiation of immune cell activation occurs through binding to the HSPG co-receptor after binding to its specific receptor. Blue Bees Therapeutics has also established a discovery platform, to develop new immune modulators, and to improve already marketed immune checkpoint inhibitors. Blue Bees Therapeutics has so far secured over 2M€ seed financing in equity and grants, allowing to complete BB10x lead product validation. The Company research laboratory has been established within the CEA Paris-Saclay campus.

Contact : Philippe Berthon, CEO : ph.berthon@bbtx.fr

Further info : <https://www.bbtx.fr/>